ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N91019D00024-0-759102000009-1
Grant search
Key facts
Disease
COVID-19Start & end year
20202025Known Financial Commitments (USD)
$67,359,812Funder
National Institutes of Health (NIH)Principal Investigator
BETH BASELERResearch Location
United States of AmericaLead Research Institution
LEIDOS BIOMEDICAL RESEARCH, INC.Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Randomized Controlled Trial
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
This funding supports INSIGHT Protocol Number: 013, Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC). It is an international multicenter, adaptive, randomized double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of anti-coronavirus hyperimmune intravenous immunoglobulin for the treatment of adult hospitalized patients at the onset of clinical progression of COVID-19.